These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 24837013)

  • 1. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
    Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
    Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
    Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
    Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs immediate radical cystectomy: a single-institutional retrospective comparative study.
    Koga F; Kihara K; Fujii Y; Yoshida S; Saito K; Masuda H; Kageyama Y; Kawakami S
    BJU Int; 2009 Jul; 104(2):189-94. PubMed ID: 19154452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study.
    Hemdan T; Malmström PU; Jahnson S; Segersten U
    J Urol; 2015 Dec; 194(6):1575-81. PubMed ID: 26119672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
    Homma S; Ishii Y; Morishima Y; Yamadori T; Matsuno Y; Haraguchi N; Kikuchi N; Satoh H; Sakamoto T; Hizawa N; Itoh K; Yamamoto M
    Clin Cancer Res; 2009 May; 15(10):3423-32. PubMed ID: 19417020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer.
    Kawashima A; Nakayama M; Kakuta Y; Abe T; Hatano K; Mukai M; Nagahara A; Nakai Y; Oka D; Takayama H; Yoshioka T; Hoshida Y; Itatani H; Nishimura K; Nonomura N
    Clin Cancer Res; 2011 Apr; 17(8):2561-9. PubMed ID: 21177407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer.
    Ma X; Zhang J; Liu S; Huang Y; Chen B; Wang D
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):485-94. PubMed ID: 21842204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
    Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
    Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
    Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
    Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines.
    Skowron MA; Niegisch G; Albrecht P; van Koeveringe G; Romano A; Albers P; Schulz WA; Hoffmann MJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.
    Kawasaki Y; Ishigami S; Arigami T; Uenosono Y; Yanagita S; Uchikado Y; Kita Y; Nishizono Y; Okumura H; Nakajo A; Kijima Y; Maemura K; Natsugoe S
    BMC Cancer; 2015 Jan; 15():5. PubMed ID: 25588809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
    Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients.
    Koga F; Numao N; Saito K; Masuda H; Fujii Y; Kawakami S; Kihara K
    Urol Oncol; 2013 Oct; 31(7):1270-5. PubMed ID: 22386622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling.
    Fan Y; Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y
    FEBS J; 2014 Apr; 281(7):1750-8. PubMed ID: 24495014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.
    Inoue K; Slaton JW; Karashima T; Yoshikawa C; Shuin T; Sweeney P; Millikan R; Dinney CP
    Clin Cancer Res; 2000 Dec; 6(12):4866-73. PubMed ID: 11156246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results.
    Bamias A; Deliveliotis C; Karayiannis A; Varkarakis I; Zervas I; Pantazopoulos D; Gika D; Dimopoulos MA
    Eur Urol; 2004 Sep; 46(3):344-50; discussion 350-1. PubMed ID: 15306106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.